Welcome to the e-CCO Library!

OP034: The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Calafat1,2*, M. Mañosa3,4, F. Cañete3, J. Panés4,5, V. García Sánchez4,6, M. Calvo7, F. Rodríguez-Moranta8, C. Taxonera9, P. Nos4,10, A. López Sanromán11, M.D. Martín Arranz12, M. Mínguez13, J.P. Gisbert4,14, S. García-López15, R. de Francisco16, F. Gomollón4,17, X. Calvet4,18, E. Garcia-Planella19, M. Rivero20, J. Martínez-Cadilla21, F. Argüelles22, L. Arias García23, M. Cimavilla24, Y. Zabana4,25, L. Márquez26, A. Gutiérrez4,27, G. Alcaín28, P. Martínez Montiel29, J. Lázaro30, D. Busquets31, M.F. García Sepulcre32, C. Verdejo33, F. Bermejo34, M. Mora35, D. Monfort36, P. Romero37, B. Velayos38, C. Rodríguez39, A. Rodríguez40, O. Merino41, A. Rodríguez-Pescador42, L. Bujanda4,43, Y. Ber44, M. Vela45, O. Roncero46, J.M. Huguet47, O. García-Bosch48, M. Barreiro-de-Acosta49, R.E. Madrigal50, L. Ramos51, M. Van Domselaar52, P. Almela53, J. Llaó54, A.J. Lucendo4,55, C. Muñoz Vilafranca56, À. Abad57, M. Charro58, J. Legido59, J. Riera1, S. Khorrami60, E. Sesé61, A.M. Trapero62, E. Domènech3,4

Created: Thursday, 21 February 2019, 9:14 AM
OP035: Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sandborn W.J.1, Cyrille M.2, Berner Hansen M.3, Feagan B.G.4, Loftus Jr. E.V.5, Vermeire S.6, Cruz M.L.2, Mo M.2, Sullivan B.A.2, Reinisch W.*7

Created: Wednesday, 20 February 2019, 10:36 AM
OP035: NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Walker1,2*, J. Harrison3, M. Voskuil4, G. Heap1,2, N. Heerasing1,2, P. Hendy1,2, J. Koskela5,6, M. Daly5,6, H. Sokol7, D. McGovern8, R. Weersma4, C. Bewshea1, M. Weedon3, J. Goodhand1,2, N. Kennedy1,2, T. Ahmad1,2, IBD Pharmacogenetics Study Group

Created: Thursday, 21 February 2019, 9:14 AM
OP036: Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with inflammatory bowel disease: a nationwide cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. de Jong1*, S. van Tilburg1,2, L. Nissen2, W. Kievit1, I. Nagtegaal3, F. Hoentjen1, L. Derikx1,2

Created: Thursday, 21 February 2019, 9:14 AM
OP036: Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Costello S.*1,2,3, Waters O.4, Bryant R.2,3, Katsikeros R.3, Makanyanga J.4, Schoeman M.2,3, Mountifield R.5, Tee D.6, Howell S.2, Hughes P.2, Conlon M.7, Roberts-Thomson I.1,2, Andrews J.2,3

Created: Wednesday, 20 February 2019, 10:36 AM
OP037: Infants born to mothers with inflammatory bowel disease exhibit distinct microbiome features that persist up to 3 months of life
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Torres J.*1, Hu J.2, Eisele C.2, Nair N.2, Panchal H.2, Bao X.2, Niu X.2, Côté-Daigneault J.1, Jharap B.1, Maser E.1, Kornbluth A.1, Legnani P.1, George J.1, Dubinsky M.3, Stone J.4, Chen C.-L.4, Clemente J.2,5, Colombel J.-F.1, Peter I.2

Created: Wednesday, 20 February 2019, 10:36 AM
OP037: Risk of cancer in inflammatory bowel disease patients is associated with age and recent use of immunomodulators, while biologics and aminosalicylates are protective factors: a cross-sectional and follow-up analysis of the Swiss IBD cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Greuther1*, S. Scharl1, C. Barthel1, J.-B. Rossel2, L. Biedermann1, B. Misselwitz1, S. Vavricka1, G. Rogler1, M. Scharl1, on behalf of the Swiss IBD Cohort Study Group

Created: Thursday, 21 February 2019, 9:14 AM
OP038: Hobit- and Blimp1-driven tissue resident memory T cells critically control chronic intestinal inflammation
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Zundler1*, E. Becker1, M. Spocinska1, L. Parga-Vidal2, R. Stark2, R. Atreya1, T. Rath1, M. Leppkes1, C. Neufert1, I. Atreya1, K. van Gisbergen2, M.F. Neurath1

Created: Thursday, 21 February 2019, 9:14 AM
OP038: Impact of ileocecal resection in Crohn's disease patients on mucosal microbiota
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Machiels K.*1, Pozuelo del Río M.2, Sabino J.1, Santiago A.2, Campos D.2, Wolthuis A.3, De Buck van Overstraeten A.3, D'Hoore A.3, Van Assche G.1, Ferrante M.1, Rutgeerts P.1, De Hertogh G.3, Vermeire S.1, Manichanh C.2

Created: Wednesday, 20 February 2019, 10:36 AM
OP03: Anti-SARS-CoV2 antibody responses are attenuated in patients with Inflammatory Bowel Disease treated with infliximab
Year: 2021
Source: ECCO'21 Virtual
Authors: Kennedy, N.A.(1);Goodhand, J.(1);Bewshea, C.(1);Nice, R.(2);Chee, D.(1);Lin, S.(1);Chanchlani, N.(1);Butterworth, J.(3);Cooney, R.(4);Croft, N.(5);Hart, A.(6);Irving, P.(7);Kok, K.(8);Lamb, C.(9);Limdi, J.(10);MacDonald, J.(11);McGovern, D.(12);Mehta, S.(13);Murray, C.(14);Patel, K.(15);Pollok, R.(15);Raine, T.(16);Russell, R.(17);Selinger, C.(18);Smith, P.(19);Bowden, J.(20);McDonald, T.(2);Lees, C.(21);Sebastian, S.(22);Powell, N.(23);Ahmad, T.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
OP03: Highly stable epigenome-wide peripheral blood DNA methylation signatures accurately predict endoscopic response to adalimumab, vedolizumab and ustekinumab in Crohn's disease patients: The EPIC-CD study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: JoustraMD., V.(1)*;Li Yim, A.(2,3);Hageman, I.(2);Levin, E.(4);Noble, A.(5);Chapman, T.(6);McGregor, C.(6);Adams, A.(6);Satsangi, J.(6);de Jonge, W.(2);Henneman, P.(3);D'Haens, G.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP03: Inhibition of autophagy exacerbates intestinal fibrosis and EMT
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Cosin-Roger*1,2, D. Ortiz-Masia3, F. Canet1, A. Trescoli-Garcia1, S. Calatayud1, M. D. Barrachina1

Created: Friday, 22 February 2019, 9:41 AM
OP03: Standardized faecal microbiota transplantation with microbiome-guided donor selection in active UC patients: A randomized, placebo-controlled intervention study
Year: 2022
Source: ECCO'22
Authors: Caenepeel, C.(1,2);Deleu, S.(1);Arnauts, K.(1);Vazquez Castellanos, J.F.(3);Braekeleire, S.(1);Machiels, K.(1);Baert, F.(4);Mana, F.(5);Pouillon, L.(6);Hindryckx, P.(7);Lobaton, T.(7);Louis, E.(8);Franchimont, D.(9);Ferrante, M.(1,2);Sabino, J.(1,2);Vieira-Silva, S.(3);Falony, G.(3);Raes, J.(3);Vermeire, S.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
OP04 Long-term outcomes after ileocolonic resection in Crohn’s disease according to the severity of early endoscopic recurrence
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Hammoudi1, C. Auzolle1, M.L. Tran Minh1, G. Boschetti2, M. Bezault3, A. Buisson4, B. Pariente5, X. Treton6, P. Seksik7, M. Fumery8, L. Le Bourhis9, S. Nancey2, M. Allez1, REMIND Study Group

Created: Thursday, 30 January 2020, 10:12 AM
OP04: Efficacy of upadacitinib in ulcerative colitis: A phase 3 post hoc analysis of biologic- and anti-TNF-inadequate response patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vermeire, S.(1)*;Danese, S.(2);Hébuterne, X.(3);D'Haens, G.(4);Takeuchi, K.(5);Finney-Hayward, T.(6);Klaff, J.(6);Holweg, C.T.J.(6);Rubin, D.T.(7);
Created: Friday, 14 July 2023, 10:43 AM
OP04: Safety analysis of filgotinib for Ulcerative Colitis: Results from the phase 2b/3 SELECTION study and phase 3 SELECTIONLTE long-term extension study
Year: 2021
Source: ECCO'21 Virtual
Authors: Schreiber, S.W.(1);Watanabe, M.(2);Yun, C.(3);Zhou, Y.(3);Zhao, S.(3);Hsieh, J.(3);Moerch, U.(4);Rogler, G.(5);Loftus Jr, E.V.(6)
Created: Wednesday, 2 June 2021, 4:12 PM
OP04: Turning sweet in inflammatory bowel disease: glycans as novel immunomodulators of T-cell-mediated immune response
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Dias1, M. Pereira1, A. Correia1, I. Alves1, V. Pinto1, L. Azevedo2, L. Maia3, R. Marcos-Pinto3, M. Vilanova1, P. Lago3, S. Pinho*1

Created: Friday, 22 February 2019, 9:41 AM
OP04: Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial
Year: 2022
Source: ECCO'22
Authors: Travis, S.(1);Silverberg, M.S.(2);Danese, S.(3);Gionchetti, P.(4);Löwenberg, M.(5);Jairath, V.(6,7);Feagan, B.G.(7);Bressler, B.(8);Lindner, D.(9);Escher, A.(9);Jones, S.(9);Shen, B.(10);
Created: Friday, 11 February 2022, 3:52 PM
OP05 Validation of the Lémann index in Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Pariente1, J. Torres2, J. Burisch3, N. Arebi4, B. Barberio5, D. Duricova6, P. Ellul7, A. Goldis8, I. Kaimakliotis9, K. Katsanos10, Z. Krznaric11, D. Mc Namara12, N. Pedersen13, S. Sebastian14, P. Weimars15, P. Lung16, C. Lacognata17, M. Horak18, V. Domislovic11, I. Murphy12, R. Ungaro19, J.F. Colombel19, J.Y. Mary20

Created: Thursday, 30 January 2020, 10:12 AM
OP05: Association of ultra-processed food intake with risk of Inflammatory Bowel Disease from the prospective urban rural epidemiology (PURE) study: A prospective cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Narula, N.(1);Wong, E.(1);Dehghan, M.(2);Mente, A.(2);Rangarajan, S.(2);Marshall, J.(1);Moayyedi, P.(1);Reinisch, W.(3);Yusuf, S.(2)
Created: Wednesday, 2 June 2021, 4:12 PM